+

US20020141944A1 - Stable pharmaceutical budersonide preparation for producing propellant-free aerosols - Google Patents

Stable pharmaceutical budersonide preparation for producing propellant-free aerosols Download PDF

Info

Publication number
US20020141944A1
US20020141944A1 US10/102,495 US10249502A US2002141944A1 US 20020141944 A1 US20020141944 A1 US 20020141944A1 US 10249502 A US10249502 A US 10249502A US 2002141944 A1 US2002141944 A1 US 2002141944A1
Authority
US
United States
Prior art keywords
pharmaceutical preparation
ethanol
propellant
active substance
free
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/102,495
Inventor
Bernhard Freund
Michael Krueger
Bernd Zierenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7765285&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US20020141944(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Individual filed Critical Individual
Priority to US10/102,495 priority Critical patent/US20020141944A1/en
Publication of US20020141944A1 publication Critical patent/US20020141944A1/en
Priority to US10/373,515 priority patent/US20030165435A1/en
Priority to US11/351,095 priority patent/US20060127322A1/en
Priority to US11/968,903 priority patent/US8062626B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/12—Aerosols; Foams
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Definitions

  • the present invention relates to pharmaceutical preparations in the form of stable ethanolic solutions of active substances for producing propellant-free aerosols.
  • nebulisers are described, for example, in PCT Patent Application WO91/14468, the contents of which are referred to hereinafter.
  • solutions of defined volumes containing active substances are sprayed, using high pressures through small nozzles so as to produce inhalable aerosols with a preferred particle size of between 1 and 10, preferably between 2 and 5 micrometres.
  • Suitable solvents for the pharmaceutical preparation within the scope of the present inventions are solutions containing at least 70% (v/v) of ethanol; solutions containing at least 85% (v/v) are preferred whilst solutions having an ethanol content of more than 95% (v/v) are particularly preferred.
  • the concentration is given in percent by volume (v/v), the remainder being water.
  • Most particularly preferred is ethanol which already contains small amounts of water, e.g. 96% ethanol, so that it is no longer hygroscopic and evaporates azeotropically.
  • the solvent may include other cosolvents and the pharmaceutical preparation may also contain flavourings and other pharmacological excipients.
  • cosolvents are those which contain hydroxyl groups or other polar groups, e.g. alcohols, especially isopropyl alcohol, glycols, particularly propylene glycol, polyethylene glycol, polypropylene glycol, glycol ether, glycerol, polyoxyethylene alcohols and esters of polyoxyethylene fatty acids.
  • Cosolvents are suitable for increasing the solubility of the excipients and possibly the active substances.
  • the proportion of dissolved pharmaceutical substance in the finished pharmaceutical preparation is between 0.001 and 5%, preferably between 0.05 and 3%, most particularly 0.01 to 2%, where the figures refer to the percentage by weight.
  • the maximum concentration of pharmaceutical substance depends on the solubility in the solvent and on the dosage required to achieve the desired therapeutic effect.
  • any substances which are suitable for administration by inhalation and which are soluble in the solvent specified may include, in particular, betamimetics, anticholinergics, antiallergics, PAF-antagonists and particularly steroids and combinations of active substances thereof.
  • WEB 2086 (4-(2-chlorophenyl)-9-methyl-2-[3-(4-morpholinyl)-3-propanon-1-yl]-6H-thieno-[3,2-f] [1,2,4]-triazolo[4,3-a][1,4]diazepine)
  • compositions according to the invention may contain other excipients such as soya lecithin or surface-active substances.
  • inorganic acids include, for example: hydrochloric acid, sulphuric acid or phosphoric acid
  • organic acids include ascorbic acid, malic acid, citric acid, tartaric acid, maleic acid, succinic acid, fumaric acid, acetic acid, formic acid, propionic acid, etc.
  • the amount of acid in the finished pharmaceutical preparation is in every case selected so that the pH of the solution is between 2.0 and 7.0, especially between 3.0 and 4.0.
  • the pharmaceutical preparation also contains a complex forming agent.
  • complex forming agents include EDTA, citric acid, nitrilo triacetic acid and the salts thereof.
  • the quantity of complex forming agent is between 0.1 and 3 mg/100 ml, preferably between 0.2 and 2 mg/100 ml, particularly between 0.9 and 1.1 mg/100 ml, based on the finished pharmaceutical preparation.
  • the preferred complex forming agent is EDTA (ethylene diamine tetraacetic acid or a salt thereof, such as the disodium salt).
  • a preferred pharmaceutical preparation according to the present invention contains 1.667% Flunisolide in the ethanol (96% v/v) as solvent, which contains 0.01% (v/v) EDTA as complex forming agent and is adjusted by the addition of acid to a pH of between 3.0 and 4.0.
  • steroids which may be used as an active substance in the pharmaceutical preparation according to the invention are: Seratrodast Mycophenolate mofetil Pranlukast Zileuton Butixocort Budesonide Deflazacort Fluticasone Promedrol Mometasone furoate Tipredane Beclomethasone, Douglas Icomethasone enbutate Ciclometasone Cloprednol Fluocortin butyl Halometasone Deflazacort Alclometasone Ciclometasone Alisactide Prednicarbate Hydrocortisone butyrate Tixocortol pivalate Alclometasone dipropionate Lotrisone Canesten-HC Deprodone Fluticasone propionate Methylprednisalone- Halopredone acetate Aceponate Mometasone Mometasone furoate Hydrocortisone aceponate Mometasone Ulobeta
  • Flunisolide hemihydrate-6a-fluoro-11 ⁇ ,16 ⁇ , 17 ⁇ , 21tetrahydropregna-1,4-diene-3,20-16 acetonide hemihydrate has a molecular weight of 442.5.
  • 250 ⁇ g of Flunisolide are dissolved, per dose, in 15 Al of solution so as to give a concentration of 1.667% (g/100 ml).
  • the finished pharmaceutical preparation contains 1 mg/100 ml of disodium-EDTA.
  • the pH value of the pharmaceutical preparation is adjusted to pH 4 using 0.1N HCl.
  • the Flunisolide-hemihydrate content was 1,666.7 mg/100 ml.
  • the pH of the solution was adjusted using 1N HCl and was determined using a pH meter, pH 1162 Radiometer Copenhagen.
  • the samples were transferred into 5 ml glass ampoules and stored at 80° C. away from light.
  • the combination AC showed the lowest amount of decomposition product after 30 days' storage.
  • the adjuvant menthol was added in order to mask the bitter flavour of the steroid where necessary.
  • compositions described above were packaged in 5 ml glass ampoules and stored at 80° C.
  • the preferred preparation on account of the small amount of decomposition product, is preparation III.
  • Table IV shows some examples of formulations for Budenoside.
  • TABLE IV I II III IV V Amount in Amount in Amount in Amount in Amount in Ingredients mg/100 ml mg/100 ml mg/100 ml mg/100 ml mg/100 ml mg/100 ml mg/100 ml.
  • Budesonide 1333 1333 1333 1333 Disodium 1 — 1 1 — EDTA 0.1N HCl 3.2 3.2 3.6 4.0 4.0 ad pH Ethanol 96% 100 100 100 100 100 100 100 100 100 100 100 100 ad

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

The invention relates to ethanol-containing pharmaceutical preparations for the production of propellant-free aerosols.

Description

  • The present invention relates to pharmaceutical preparations in the form of stable ethanolic solutions of active substances for producing propellant-free aerosols. [0001]
  • In the last 20 years, the use of metering aerosols has become an established component of the treatment of obstructive lung diseases, particularly asthma. Usually, fluorochlorohydrocarbons have been used as propellant gases. Since the ozone-damaging potential of these propellant gases was recognised, more and more efforts have been made to develop alternatives. One alternative is the development of nebulisers in which aqueous solutions of pharmacologically-active substances are sprayed under high pressure so as to produce a mist of inhalable particles. The advantage of these nebulisers is that there is no need to use any propellant gases whatsoever. [0002]
  • Some nebulisers are described, for example, in PCT Patent Application WO91/14468, the contents of which are referred to hereinafter. In the nebulisers described therein, solutions of defined volumes containing active substances are sprayed, using high pressures through small nozzles so as to produce inhalable aerosols with a preferred particle size of between 1 and 10, preferably between 2 and 5 micrometres. [0003]
  • Hitherto, it has been assumed that, with conventional metering aerosols containing propellant gas, the optimum level of lung-bound particles is obtained in the aerosol. It has now been found, surprisingly, that by using ethanolic active substance solutions in combination with, for example, the above-mentioned nebulisers it is possible to generate a significantly better spectrum of inhalable particles than is usually the case with metering aerosols which contain propellant gas. [0004]
  • Suitable solvents for the pharmaceutical preparation within the scope of the present inventions are solutions containing at least 70% (v/v) of ethanol; solutions containing at least 85% (v/v) are preferred whilst solutions having an ethanol content of more than 95% (v/v) are particularly preferred. The concentration is given in percent by volume (v/v), the remainder being water. Most particularly preferred is ethanol which already contains small amounts of water, e.g. 96% ethanol, so that it is no longer hygroscopic and evaporates azeotropically. [0005]
  • Apart from water, the solvent may include other cosolvents and the pharmaceutical preparation may also contain flavourings and other pharmacological excipients. Examples of cosolvents are those which contain hydroxyl groups or other polar groups, e.g. alcohols, especially isopropyl alcohol, glycols, particularly propylene glycol, polyethylene glycol, polypropylene glycol, glycol ether, glycerol, polyoxyethylene alcohols and esters of polyoxyethylene fatty acids. Cosolvents are suitable for increasing the solubility of the excipients and possibly the active substances. [0006]
  • The proportion of dissolved pharmaceutical substance in the finished pharmaceutical preparation is between 0.001 and 5%, preferably between 0.05 and 3%, most particularly 0.01 to 2%, where the figures refer to the percentage by weight. The maximum concentration of pharmaceutical substance depends on the solubility in the solvent and on the dosage required to achieve the desired therapeutic effect. [0007]
  • As pharmaceutically active agent in the new preparations, it is possible to use any substances which are suitable for administration by inhalation and which are soluble in the solvent specified. These may include, in particular, betamimetics, anticholinergics, antiallergics, PAF-antagonists and particularly steroids and combinations of active substances thereof.[0008]
  • The following are mentioned specifically by way of example: [0009]
  • Tiotropium bromide, 3-[(hydroxydi-2-thienylacetyl)oxy]-8,8-dimethyl-8-azoniabicyclo[3,2,1] oct-6-en-bromide [0010]
  • As betamimetics: [0011]
    Bambuterol Bitolterol Carbuterol Formoterol
    Clenbuterol Fenoterol Hexoprenaline Procaterol
    Ibuterol Pirbuterol Salmeterol Tulobuterol
    Reproterol Salbutamol Sulfonterol Terbutaline
  • 1-(2-fluoro-4-hydroxyphenyl)-2-[4-(1-benzimidazolyl)-2-methyl-2-butylamino]ethanol, erythro-5′-hydroxy-8′-(1-hydroxy-[0012]
  • 2-isopropylaminobutyl)-2H-1,4-benzoxazin-3-(4H)-one, [0013]
  • 1-(4-amino-3-chloro-5-trifluoromethylphenyl)-2-tert.-butyl-amino)ethanol, [0014]
  • 1-(4-ethoxycarbonylamino-3-cyano-5-fluorophenyl)-2-(tert.-butylamino)ethanol. [0015]
  • As anticholinergics: [0016]
  • Ipratropium bromide [0017]
  • Oxitropium bromide [0018]
  • Trospium chloride [0019]
  • N-β-fluorethylnortropine benzilate methobromide [0020]
  • As steroids: [0021]
  • Budesonide [0022]
  • Beclomethasone (or the 17,21-dipropionate) [0023]
  • Dexamethasone-21-isonicotinate [0024]
  • Flunisolide [0025]
  • As antiallergics: [0026]
  • Disodium cromoglycate [0027]
  • Nedocromil [0028]
  • Epinastin [0029]
  • As PAF-antagonists: [0030]
  • WEB 2086 (4-(2-chlorophenyl)-9-methyl-2-[3-(4-morpholinyl)-3-propanon-1-yl]-6H-thieno-[3,2-f] [1,2,4]-triazolo[4,3-a][1,4]diazepine) [0031]
  • WEB 2170 [0032]
  • (6-(2-chlorophenyl)-8,9-dihydro-l-methyl-8-[(4-morpholinyl)carbonyl]-4H,7H-cyclopenta[4,5]thieno-[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine) [0033]
  • The pharmaceutical preparations according to the invention may contain other excipients such as soya lecithin or surface-active substances. [0034]
  • Surprisingly, it has also been found that the addition of an organic or inorganic acid, preferably in conjunction with a complex forming agent, leads to an improvement in the stability (shelf life) of steroid-containing preparations. This has been found particularly useful for pharmaceutical preparations which contain as active substance Flunisolide or the hydrate or hemihydrate thereof or Budenoside, and which contain ethanol as solvent. [0035]
  • Examples of inorganic acids include, for example: hydrochloric acid, sulphuric acid or phosphoric acid; examples of organic acids include ascorbic acid, malic acid, citric acid, tartaric acid, maleic acid, succinic acid, fumaric acid, acetic acid, formic acid, propionic acid, etc. [0036]
  • The amount of acid in the finished pharmaceutical preparation is in every case selected so that the pH of the solution is between 2.0 and 7.0, especially between 3.0 and 4.0. [0037]
  • In a preferred embodiment, the pharmaceutical preparation also contains a complex forming agent. Examples of complex forming agents include EDTA, citric acid, nitrilo triacetic acid and the salts thereof. The quantity of complex forming agent is between 0.1 and 3 mg/100 ml, preferably between 0.2 and 2 mg/100 ml, particularly between 0.9 and 1.1 mg/100 ml, based on the finished pharmaceutical preparation. [0038]
  • The preferred complex forming agent is EDTA (ethylene diamine tetraacetic acid or a salt thereof, such as the disodium salt). A preferred pharmaceutical preparation according to the present invention contains 1.667% Flunisolide in the ethanol (96% v/v) as solvent, which contains 0.01% (v/v) EDTA as complex forming agent and is adjusted by the addition of acid to a pH of between 3.0 and 4.0. [0039]
  • Examples of steroids which may be used as an active substance in the pharmaceutical preparation according to the invention are: [0040]
    Seratrodast Mycophenolate mofetil
    Pranlukast Zileuton
    Butixocort Budesonide
    Deflazacort
    Fluticasone Promedrol
    Mometasone furoate Tipredane
    Beclomethasone, Douglas Icomethasone enbutate
    Ciclometasone Cloprednol
    Fluocortin butyl Halometasone
    Deflazacort Alclometasone
    Ciclometasone Alisactide
    Prednicarbate Hydrocortisone butyrate
    Tixocortol pivalate Alclometasone dipropionate
    Lotrisone Canesten-HC
    Deprodone Fluticasone propionate
    Methylprednisalone- Halopredone acetate
    Aceponate
    Mometasone Mometasone furoate
    Hydrocortisone aceponate Mometasone
    Ulobetasol propionate Aminoglutethimide
    Triamcinolone Hydrocortisone
    Meprednisone Fluorometholone
    Dexamethasone Betamethasone
    Medrysone Fluclorolone acetonide
    Fluocinolone acetonide Paramethasone acetate
    Deprodone Propionate Aristocort diacetate
    Fluocinonide Mazipredone
    Difluprednate Betamethasone valerate
    Dexamethasonisonicotinate Beclomethasone dipropionate
    Fluocortoloncapronate Formocortal
    Triamcinolon hexacetonide Cloprednol
    Formebolone Clobetason
    Endrisone Flunisolide
    Halcinonide Fluazacort
    Clobetasol Hydrocortisone-17-butyrate
    Diflorasone Flucortin
    Amcinonide Betamethasone dipropionate
    Cortivazol Betamethasone adamantoate
    Fluodexan Triiostane
    Budesonide Clobetasone
    Demetex Trimacinolon Benetonide
  • 9α-chloro-6a-fluoro-11β,17α-dihydroxy-16α-methyl-3-oxo-1,4-androstadiene-17β-carboxylic acid methylester-17-propionate. [0041]
  • Table 1 shows a comparison of a deposition study which was carried out on the one hand with a standard commercial metering aerosol Inhacort® (Flunisolide, dichloromethane, trichlorofluoromethane, cryofluoran, sorbitane triolate)=MDI, and on the other hand with the pharmaceutical preparation according to the invention containing Flunisolide in 96% (v/v) ethanol, which was carried out with a nebuliser as in the above-mentioned PCT Application WO 91/14468 (BINEB®; technical data: volume of drug preparation administered 15 μl, pressure approx. 300 bar, 2 jets squeezed out of two nozzle openings measuring 5×8 μm). [0042]
    TABLE I
    Deposition study
    BINEB ® MDI
    Lung (%) 39.7 (9.9) 15.3 (5.1)
    Mouthpiece (%) 39.9 (9.4) 66.9 (7.1)
    Exhaled part (%) 10.4 (4.9)  1.4 (1.3)
    Central lung region (%) 10.7 (2.5)  4.5 (1.8)
    Middle lung region (%) 14.9 (3.6)  5.4 (1.9)
    Peripheral lung region (%) 14.1 (4.3)  5.4 (1.4)
    Peripheral zone/central  1.3 (0.2)  1.3 (0.2)
    zone ratio
  • The Table clearly shows the advantage of the pharmaceutical preparation according to the invention which was administered with the nebuliser described. [0043]
    • EXAMPLES
  • Flunisolide hemihydrate-6a-fluoro-11Δ,16α, 17α, 21tetrahydropregna-1,4-diene-3,20-16 acetonide hemihydrate has a molecular weight of 442.5. When used in BINEB, 250 μg of Flunisolide are dissolved, per dose, in 15 Al of solution so as to give a concentration of 1.667% (g/100 ml). [0044]
  • 96% ethanol is used as solvent. In addition, the finished pharmaceutical preparation contains 1 mg/100 ml of disodium-EDTA. The pH value of the pharmaceutical preparation is adjusted to pH 4 using 0.1N HCl. [0045]
  • Analogously to the above experiment, formulations were prepared containing Budesonide as active substance. [0046]
  • The following mixtures of pharmaceutical preparations were made up, containing Flunisolide-hemihydrate as active substance. [0047]
    TABLE II
    Quantity of
    Ethanol disodium
    Experiment content EDTA in
    No. Combination (v/v) % pH mg/100 ml
    1 1 85 3.6 0
    2 A 96 3.6 0
    3 B 85 7.0 0
    4 AB 96 7.0 0
    5 C 85 3.6 1
    6 AC 96 3.6 1
    7 BC 85 7.0 1
    8 ABC 96 7.0 1
  • The Flunisolide-hemihydrate content was 1,666.7 mg/100 ml. The pH of the solution was adjusted using 1N HCl and was determined using a pH meter, pH 1162 Radiometer Copenhagen. The samples were transferred into 5 ml glass ampoules and stored at 80° C. away from light. The combination AC showed the lowest amount of decomposition product after 30 days' storage. [0048]
  • Further examples of formulations which additionally contain disodium EDTA as complex forming agent are shown in Table III. [0049]
    TABLE III
    I II III IV
    Amount in Amount in Amount in Amount in
    Ingredients mg/100 ml mg/100 ml mg/100 ml mg/100 ml
    Flunisolide 1667 1667 1667 1667
    hemihydrate
    Disodium 1 1 1 1
    EDTA
    0.1 N HCl ad pH 3.6 ad pH 3.2 ad pH 4.0 ad pH 3.6
    Menthol — — — 667
    Ethanol 96% ad 100 ml ad 100 ml ad 100 ml ad 100 ml
  • The adjuvant menthol was added in order to mask the bitter flavour of the steroid where necessary. [0050]
  • The formulations described above were packaged in 5 ml glass ampoules and stored at 80° C. The preferred preparation, on account of the small amount of decomposition product, is preparation III. [0051]
  • Table IV shows some examples of formulations for Budenoside. [0052]
    TABLE IV
    I II III IV V
    Amount in Amount in Amount in Amount in Amount in
    Ingredients mg/100 ml mg/100 ml mg/100 ml mg/100 ml mg/100 ml
    Budesonide 1333 1333 1333 1333 1333
    Disodium 1 — 1 1 —
    EDTA
    0.1N HCl 3.2 3.2 3.6 4.0 4.0
    ad pH
    Ethanol 96% 100 100 100 100 100
    ad
  • After 3 months' storage at 80° C. in sealed [0053]
  • glass ampoules the amount of decomposition product was determined by HPLC. Formulations IV and V showed the smallest amount of decomposition product. [0054]

Claims (20)

1. A pharmaceutical preparation for use in producing propellant-free aerosols which comprises a pharmacologically active substance, and if necessary, pharmacologically-harmless adjuvants and/or flavourings, characterised in that the pharmaceutical preparation contains at least 70% (v/v) ethanol as a solvent.
2. A pharmaceutical preparation according to claim 1, characterised in that it contains 96% (v/v) ethanol as a solvent.
3. A pharmaceutical preparation according to claim 1 or 2, characterised in that the active substance is suitable for administration by inhalation and is selected from the group comprising betamimetics, anticholinergics, antiallergics and/or PAF-antagonists.
4. A pharmaceutical preparation according to claims 1 to 3, characterised in that the proportion of dissolved pharmaceutical product in the pharmaceutical preparation is between 0.001 and 5.0 percent by volume.
5. A pharmaceutical preparation for the production of propellant-free aerosols, comprising a steroid and, if necessary, pharmacologically-harmless adjuvants and/or flavourings, characterised in that the pharmaceutical preparation contains at least 85% (v/v) ethanol as a solvent, and if necessary, a complex forming agent.
6. A pharmaceutical preparation according to claim 5, characterised in that the solvent is 96% (v/v) ethanol.
7. A pharmaceutical preparation according to claim 6, characterised in that the complex forming agent is EDTA or a salt thereof.
8. A pharmaceutical preparation according to claim 5 or claim 7, characterised in that the quantity of complex forming agent is between 0.1 and 5 mg/100 ml of solution.
9. A pharmaceutical preparation according to one of claims 5 to 8, characterised in that the pH value of the preparation is adjusted to a level between 3.2 and 4.5.
10. A pharmaceutical preparation according to one of claims 5 to 9, characterised in that the active substance is Flunisolide or Budesonide.
11. A pharmaceutical preparation according to one of claims 1 to 6, characterised in that the active substance is Tiotropium or an acid addition salt thereof.
12. A pharmaceutical preparation according to one of claims 1 to 6, characterised in that the active substance is 3-[(hydroxydi-2-thienylacetyl)oxy]-8,8-dimethyl-8-azoniabicyclo[3,2,]oct-6-ene or an acid addition salt thereof.
13. A pharmaceutical preparation for use in producing a propellant-free metering aerosol containing, per 100 ml of 96% (v/v) ethanol, 1.667 g of Flunisolide hemihydrate and 1 mg of disodium EDTA, the pH value of the pharmaceutical preparation being adjusted to 4.0.
14. A pharmaceutical preparation for use in producing a propellant-free metering aerosol containing, per 100 ml of 90% (v/v) ethanol, 1.667 g of Flunisolide hemihydrate and 1 mg of disodium EDTA, the pH value of the pharmaceutical preparation being adjusted to 4.0.
15. A pharmaceutical preparation for use in producing a propellant-free metering aerosol containing, per 100 ml of 96% (v/v) ethanol, 1.333 g of Budesonide and 1 mg of disodium EDTA, the pH value of the pharmaceutical preparation being adjusted to 4.0.
16. A pharmaceutical preparation for use in producing a propellant-free metering aerosol containing, per 100 ml of 90% (v/v) ethanol, 1.333 g of Budesonide and 1 mg of disodium EDTA, the pH value of the pharmaceutical preparation being adjusted to 4.0.
17. Use of a pharmaceutical preparation comprising a pharmacologically active substance in a solution containing at least 79% ethanol by volume in the preparation of a propellant-free composition for administration by inhalation.
18. Use of a pharmaceutical preparation as defined in one of claims 1 to 16 as a propellant-free composition for administration by inhalation.
19. A process for preparing a pharmaceutical preparation as defined in claim 1 which comprises dissolution of a pharmacologically active substance in at least 70% v/v.
20. A delivery system for a pharmacologically active substance which comprises a preparation as defined in any one of claims 1 to 16 in combination with a propellant-free nebuliser.
US10/102,495 1995-06-27 2002-03-20 Stable pharmaceutical budersonide preparation for producing propellant-free aerosols Abandoned US20020141944A1 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US10/102,495 US20020141944A1 (en) 1995-06-27 2002-03-20 Stable pharmaceutical budersonide preparation for producing propellant-free aerosols
US10/373,515 US20030165435A1 (en) 1995-06-27 2003-02-25 Stable pharmaceutical budesonide preparation for producing propellant-free aerosols
US11/351,095 US20060127322A1 (en) 1995-06-27 2006-02-09 Stable pharmaceutical Budesonide preparation for producing propellant-free aerosols
US11/968,903 US8062626B2 (en) 1995-06-27 2008-01-03 Stable pharmaceutical budesonide preparation for producing propellant-free aerosols

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DE19523207 1995-06-27
DE19523207.0 1995-06-27
US97392198A 1998-02-03 1998-02-03
US09/396,673 US6491897B1 (en) 1995-06-27 1999-09-09 Stable pharmaceutical budesonide preparation for producing propellant-free aerosols
US10/102,495 US20020141944A1 (en) 1995-06-27 2002-03-20 Stable pharmaceutical budersonide preparation for producing propellant-free aerosols

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US09/396,673 Continuation US6491897B1 (en) 1995-06-27 1999-09-09 Stable pharmaceutical budesonide preparation for producing propellant-free aerosols

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/373,515 Continuation US20030165435A1 (en) 1995-06-27 2003-02-25 Stable pharmaceutical budesonide preparation for producing propellant-free aerosols

Publications (1)

Publication Number Publication Date
US20020141944A1 true US20020141944A1 (en) 2002-10-03

Family

ID=7765285

Family Applications (5)

Application Number Title Priority Date Filing Date
US09/396,673 Expired - Lifetime US6491897B1 (en) 1995-06-27 1999-09-09 Stable pharmaceutical budesonide preparation for producing propellant-free aerosols
US10/102,495 Abandoned US20020141944A1 (en) 1995-06-27 2002-03-20 Stable pharmaceutical budersonide preparation for producing propellant-free aerosols
US10/373,515 Abandoned US20030165435A1 (en) 1995-06-27 2003-02-25 Stable pharmaceutical budesonide preparation for producing propellant-free aerosols
US11/351,095 Abandoned US20060127322A1 (en) 1995-06-27 2006-02-09 Stable pharmaceutical Budesonide preparation for producing propellant-free aerosols
US11/968,903 Expired - Fee Related US8062626B2 (en) 1995-06-27 2008-01-03 Stable pharmaceutical budesonide preparation for producing propellant-free aerosols

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/396,673 Expired - Lifetime US6491897B1 (en) 1995-06-27 1999-09-09 Stable pharmaceutical budesonide preparation for producing propellant-free aerosols

Family Applications After (3)

Application Number Title Priority Date Filing Date
US10/373,515 Abandoned US20030165435A1 (en) 1995-06-27 2003-02-25 Stable pharmaceutical budesonide preparation for producing propellant-free aerosols
US11/351,095 Abandoned US20060127322A1 (en) 1995-06-27 2006-02-09 Stable pharmaceutical Budesonide preparation for producing propellant-free aerosols
US11/968,903 Expired - Fee Related US8062626B2 (en) 1995-06-27 2008-01-03 Stable pharmaceutical budesonide preparation for producing propellant-free aerosols

Country Status (35)

Country Link
US (5) US6491897B1 (en)
EP (1) EP0835098B1 (en)
JP (1) JP3875993B2 (en)
KR (1) KR100392280B1 (en)
CN (1) CN1086575C (en)
AR (1) AR002614A1 (en)
AT (1) ATE223203T1 (en)
AU (1) AU721566B2 (en)
BG (1) BG64112B1 (en)
BR (1) BR9609307B1 (en)
CA (1) CA2225601C (en)
CZ (1) CZ288337B6 (en)
DE (2) DE19625027A1 (en)
DK (1) DK0835098T3 (en)
EE (1) EE03509B2 (en)
EG (1) EG23912A (en)
ES (1) ES2183001T3 (en)
HU (1) HU223072B1 (en)
IL (1) IL122752A (en)
MX (1) MX9800125A (en)
MY (1) MY116535A (en)
NO (1) NO315452B1 (en)
NZ (1) NZ312662A (en)
PE (1) PE11098A1 (en)
PL (1) PL186196B1 (en)
PT (1) PT835098E (en)
RU (1) RU2223750C2 (en)
SA (1) SA96170213B1 (en)
SI (1) SI0835098T1 (en)
SK (1) SK282468B6 (en)
TR (1) TR199701711T1 (en)
TW (1) TW537903B (en)
UA (1) UA62917C2 (en)
WO (1) WO1997001329A1 (en)
ZA (1) ZA965411B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7040314B2 (en) 2002-09-06 2006-05-09 Philip Morris Usa Inc. Aerosol generating devices and methods for generating aerosols suitable for forming propellant-free aerosols
US20070086957A1 (en) * 2005-10-10 2007-04-19 Thierry Bouyssou Combination of medicaments for the treatment of respiratory diseases

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9504265D0 (en) * 1995-03-03 1995-04-19 Medeva Plc Corticosteroid-containing pharmaceutical composition
UA62917C2 (en) * 1995-06-27 2004-01-15 Berinher Inhelheim Kg Medicinal composition for generating propellant-free aerosols
DE19615422A1 (en) 1996-04-19 1997-11-20 Boehringer Ingelheim Kg Two-chamber cartridge for propellant-free MDIs
US20030215396A1 (en) 1999-09-15 2003-11-20 Boehringer Ingelheim Pharma Kg Method for the production of propellant gas-free aerosols from aqueous medicament preparations
DE19653969A1 (en) * 1996-12-20 1998-06-25 Boehringer Ingelheim Kg New aqueous pharmaceutical preparation for the production of propellant-free aerosols
US6598603B1 (en) * 1997-12-31 2003-07-29 Astra Aktiebolag Method for treating respiratory diseases
DE19808295A1 (en) 1998-02-27 1999-11-11 Boehringer Ingelheim Int Medical fluid container
DE19847968A1 (en) 1998-10-17 2000-04-20 Boehringer Ingelheim Pharma Separate storage of an active material and a solvent comprises a closure cap and a container, with a chamber attached to the unit.
DE19940713A1 (en) 1999-02-23 2001-03-01 Boehringer Ingelheim Int Diffusion resistant cartridge for storing and dosing liquids, especially for producing drug-containing inhalable aerosols, has three-shell structure with collapsible bag, container and rigid housing
GB9904281D0 (en) * 1999-02-24 1999-04-21 Reneuron Ltd Transplantation
DE19954516A1 (en) * 1999-11-12 2001-05-17 Boehringer Ingelheim Int Solutions containing epinastine
US8820316B2 (en) * 2000-02-11 2014-09-02 Respironics Respiratory Drug Delivery (Uk) Ltd Drug delivery apparatus
GB0009583D0 (en) * 2000-04-18 2000-06-07 Glaxo Group Ltd Respiratory formulations
DE10062712A1 (en) * 2000-12-15 2002-06-20 Boehringer Ingelheim Pharma New drug compositions based on anticholinergics and corticosteroids
ME00242B (en) * 2000-10-31 2011-05-10 Boehringer Ingelheim Pharma INHALATIVE SOLUTION FORMULATION WITH A TIOTROPIUM SALT
US20020137764A1 (en) * 2000-10-31 2002-09-26 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
US20020111363A1 (en) * 2000-10-31 2002-08-15 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt
US20020193392A1 (en) * 2000-11-13 2002-12-19 Christel Schmelzer Pharmaceutical compositions based on tiotropium salts of salts of salmeterol
DE10111843A1 (en) * 2001-03-13 2002-09-19 Boehringer Ingelheim Pharma Compounds for the treatment of inflammatory diseases
DE10130371A1 (en) * 2001-06-23 2003-01-02 Boehringer Ingelheim Pharma New drug compositions based on anticholinergics, corticosteroids and betamimetics
DE10136555A1 (en) 2001-07-27 2003-02-13 Boehringer Ingelheim Int Method for determining the size distribution of particles in an aerosol, especially particles of a medicament involves mixing of a carrier medium with the medicament to produce an appropriately conditioned aerosol
US20040019073A1 (en) * 2002-04-11 2004-01-29 Boehringer Ingelheim Pharma Gmbh Co. Kg Aerosol formulation for inhalation containing a tiotropium salt
US20040166065A1 (en) * 2002-08-14 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosol formulation for inhalation comprising an anticholinergic
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
US7849850B2 (en) * 2003-02-28 2010-12-14 Battelle Memorial Institute Nozzle for handheld pulmonary aerosol delivery device
DE10345065A1 (en) 2003-09-26 2005-04-14 Boehringer Ingelheim Pharma Gmbh & Co. Kg Aerosol formulation for inhalation containing an anticholinergic
AR041873A1 (en) * 2003-10-30 2005-06-01 Pablo Cassara Srl Lab A PHARMACEUTICAL FORMULATION IN ADEQUATE AEROSOL FOR ORAL OR NASAL INHALATION CONTAINING GLUCOCORTICOIDS IN A STABLE SOLUTION TO STORAGE; A METHOD FOR STABILIZING FORMULATIONS AND USE OF A STABILIZING AGENT
DE102004001451A1 (en) 2004-01-08 2005-08-11 Boehringer Ingelheim International Gmbh Device for holding a fluidic component
RU2288757C2 (en) * 2004-04-29 2006-12-10 Общество с ограниченной ответственностью "Фирма "ВИПС-МЕД" Composition for treatment of mouth and nasal cavity diseases
US7220742B2 (en) 2004-05-14 2007-05-22 Boehringer Ingelheim International Gmbh Enantiomerically pure beta agonists, process for the manufacture thereof and use thereof as medicaments
RU2274464C2 (en) * 2004-07-01 2006-04-20 Общество с ограниченной ответственностью "Фирма "ВИПС-МЕД" Composition used in treatment of diseases of mouth and nose cavity
GB0427568D0 (en) * 2004-12-16 2005-01-19 Resolution Chemicals Ltd Particle-size reduction apparatus, and the use thereof
EP2767163A1 (en) 2005-02-17 2014-08-20 Abbott Laboratories Transmucosal administration of drug compositions for treating and preventing disorders in animals
WO2006089656A2 (en) * 2005-02-25 2006-08-31 Chiesi Farmaceutici S.P.A. Pharmaceutical aerosol formulations for pressurized metered dose inhalers comprising a sequestering agent
RU2412176C2 (en) 2005-08-15 2011-02-20 Бёрингер Ингельхайм Интернациональ Гмбх Method of producing betamimetics
EP2018224B1 (en) 2006-02-14 2019-03-06 EField Innovations LLC Dissociated discharge ehd sprayer with electric field shield
DE102006023756A1 (en) * 2006-05-20 2007-11-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Ethanol-containing aerosol formulation for inhalation
RU2356537C2 (en) * 2007-07-25 2009-05-27 Закрытое Акционерное Общество (ЗАО) "Пульмомед" Pharmaceutical composition of metered aerosols containing antiasthmatic agents in form of suspensions, solutions, emulsions, solutions and emulsions
EP2077132A1 (en) 2008-01-02 2009-07-08 Boehringer Ingelheim Pharma GmbH & Co. KG Dispensing device, storage device and method for dispensing a formulation
WO2010048384A2 (en) * 2008-10-23 2010-04-29 Sepracor Inc. Arformoterol and tiotropium compositions and methods for use
EP2414560B1 (en) 2009-03-31 2013-10-23 Boehringer Ingelheim International GmbH Method for coating a surface of a component
WO2010133294A2 (en) 2009-05-18 2010-11-25 Boehringer Ingelheim International Gmbh Adapter, inhalation device, and atomizer
US10016568B2 (en) 2009-11-25 2018-07-10 Boehringer Ingelheim International Gmbh Nebulizer
WO2011064163A1 (en) 2009-11-25 2011-06-03 Boehringer Ingelheim International Gmbh Nebulizer
PH12012501039A1 (en) 2009-11-25 2016-11-11 Boehringer Ingelheim Int Nebulizer
EP2585151B1 (en) 2010-06-24 2018-04-04 Boehringer Ingelheim International GmbH Nebulizer
WO2012130757A1 (en) 2011-04-01 2012-10-04 Boehringer Ingelheim International Gmbh Medical device comprising a container
US9827384B2 (en) 2011-05-23 2017-11-28 Boehringer Ingelheim International Gmbh Nebulizer
WO2013152894A1 (en) 2012-04-13 2013-10-17 Boehringer Ingelheim International Gmbh Atomiser with coding means
PL2835146T3 (en) 2013-08-09 2021-04-06 Boehringer Ingelheim International Gmbh Nebulizer
WO2015018904A1 (en) 2013-08-09 2015-02-12 Boehringer Ingelheim International Gmbh Nebulizer
JP6580070B2 (en) 2014-05-07 2019-09-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Container, nebulizer, and use
HUE055604T2 (en) 2014-05-07 2021-12-28 Boehringer Ingelheim Int Nebulizer
EP3928818B1 (en) 2014-05-07 2023-02-01 Boehringer Ingelheim International GmbH Nebulizer and container
EP3220852A1 (en) 2014-11-20 2017-09-27 Boehringer Ingelheim Vetmedica GmbH Container for an inhaler
CN111939143A (en) * 2019-05-16 2020-11-17 鲁南制药集团股份有限公司 Budesonide solution type aerosol and preparation method thereof
KR102278414B1 (en) 2019-12-03 2021-07-16 한전케이피에스 주식회사 A tool for changing belt
AU2021314977B2 (en) * 2020-07-31 2025-03-13 Chemo Research, S.L. Combination therapy for inhalation administration

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE632504A (en) 1962-05-24
DE1952320C3 (en) 1969-10-17 1981-02-26 Licentia Patent-Verwaltungs-Gmbh, 6000 Frankfurt Device for sealing two coaxially nested rotating or opposing shafts in watercraft
MX3864E (en) * 1975-05-27 1981-08-26 Syntex Corp A PROCESS TO PREPARE THE CRYSTALLINE COMPOUND 6-FLUIRO-11B 21-DIHIROXI-16 17-ISOPROPILIDENDIOXIPREGNA-1 4-DIEN-3 20-DIONA
JPS5529524A (en) 1978-08-21 1980-03-01 Toyo Aerosol Kogyo Kk Powdery aerosol composition
JPS599539B2 (en) 1979-11-13 1984-03-03 日本化薬株式会社 Nitroglycerin aqueous solution and its manufacturing method
US4289764A (en) * 1979-12-04 1981-09-15 Drythanol Ltd. Steroid compositions
DE3109783C2 (en) 1981-03-13 1987-04-02 Schwarz GmbH, 4019 Monheim Process for the preparation of an ethanol-free nitroglycerin solution with a concentration of about 1 mg nitroglycerin/ml
US4383992A (en) * 1982-02-08 1983-05-17 Lipari John M Water-soluble steroid compounds
DE3246081A1 (en) 1982-12-13 1984-06-14 G. Pohl-Boskamp GmbH & Co Chemisch-pharmazeutische Fabrik, 2214 Hohenlockstedt Nitroglycerin spray
JPS6183117A (en) 1984-09-28 1986-04-26 Sumitomo Chem Co Ltd aerosol agent
US4615699A (en) 1985-05-03 1986-10-07 Alza Corporation Transdermal delivery system for delivering nitroglycerin at high transdermal fluxes
DE3544692A1 (en) 1985-12-18 1987-06-19 Bayer Ag DIHYDROPYRIDINE SPRAY, METHOD FOR THE PRODUCTION THEREOF AND ITS PHARMACEUTICAL USE
AU6907687A (en) * 1986-02-18 1987-08-20 Rorer Pharmaceutical Corporation Composition for treatment of asthmatic conditions using phenoxymethyl quinolines
JPH0645538B2 (en) 1987-09-30 1994-06-15 日本化薬株式会社 Nitroglycerin spray
HU199678B (en) * 1988-07-08 1990-03-28 Egyt Gyogyszervegyeszeti Gyar Process for producing aerosols containing nitroglicerol
US5225183A (en) * 1988-12-06 1993-07-06 Riker Laboratories, Inc. Medicinal aerosol formulations
GB8828477D0 (en) * 1988-12-06 1989-01-05 Riker Laboratories Inc Medical aerosol formulations
US5136124A (en) 1988-12-14 1992-08-04 International Business Machines Corporation Method of forming conductors within an insulating substrate
GB8829478D0 (en) 1988-12-16 1989-02-01 Harris Pharma Ltd Formulations
US5370862A (en) * 1990-06-13 1994-12-06 Schwarz Pharma Ag Pharmaceutical hydrophilic spray containing nitroglycerin for treating angina
IT1243379B (en) 1990-07-27 1994-06-10 Giuliani Spa PHARMACEUTICAL COMPOSITION SUITABLE FOR RECTAL ADMINISTRATION OF ACTIVE PRINCIPLES WHICH EXPLICATE A MEDICATION ACTION AT THE LEVEL OF THE COLON, PREVALENTLY TOPICAL
MX9203481A (en) * 1990-10-18 1992-07-01 Minnesota Mining & Mfg FORMULATIONS.
WO1992006675A1 (en) * 1990-10-18 1992-04-30 Minnesota Mining And Manufacturing Company Aerosol formulation comprising beclomethasone 17,21 dipropionate
EP0504112A3 (en) 1991-03-14 1993-04-21 Ciba-Geigy Ag Pharmaceutical aerosol formulations
ES2158910T3 (en) * 1991-06-10 2001-09-16 Schering Corp FORMULATIONS IN AEROSOL WITHOUT CHLOROFLUOROCARBONOS.
DE4123663A1 (en) * 1991-07-17 1993-01-21 Schwabe Willmar Gmbh & Co Medicinal aerosol free from fluoro:chlorocarbon(s) - contains active agent in suspending or dispersing aid and alcohol with hepta:fluoro:propane as propellant
IL103238A (en) 1991-09-25 1995-07-31 Fisons Plc Pressurised aerosol compositions
US5736124A (en) * 1991-12-12 1998-04-07 Glaxo Group Limited Aerosol formulations containing P134a and particulate medicament
US5674471A (en) * 1991-12-12 1997-10-07 Glaxo Group Limited Aerosol formulations containing P134a and salbutamol
RU2014085C1 (en) * 1991-12-26 1994-06-15 Владимир Валерианович Гусев Antimicrobial composition
DE4203306A1 (en) 1992-02-06 1993-08-12 Ig Spruehtechnik Gmbh ASTHMA OR PULMONAL AEROSOL PREPARATIONS WITH LECITHIN
GB9202519D0 (en) 1992-02-06 1992-03-25 Glaxo Group Ltd Medicaments
US5224183A (en) * 1992-07-23 1993-06-29 Alcatel Network Systems, Inc. Multiple wavelength division multiplexing signal compensation system and method using same
EP0673240B1 (en) * 1992-12-09 1999-03-24 Boehringer Ingelheim Pharmaceuticals Inc. Stabilized medicinal aerosol solution formulations
DK0713386T3 (en) * 1993-08-10 1999-08-02 Boots Co Plc Spray formulation with cooling effect
DE4340057A1 (en) 1993-11-24 1995-06-01 Falk Pharma Gmbh Budesonide drugs to improve enteral fluid absorption, especially after postoperative conditions
DE4446891A1 (en) 1994-12-27 1996-07-04 Falk Pharma Gmbh Stable aqueous budesonide solution
UA62917C2 (en) 1995-06-27 2004-01-15 Berinher Inhelheim Kg Medicinal composition for generating propellant-free aerosols
US5958378A (en) * 1996-07-03 1999-09-28 Research Development Foundation High dose liposomal aerosol formulations containing cyclosporin A or budesonide
US6039932A (en) * 1996-09-27 2000-03-21 3M Innovative Properties Company Medicinal inhalation aerosol formulations containing budesonide
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
US20020137764A1 (en) * 2000-10-31 2002-09-26 Karin Drechsel Inhalable formulation of a solution containing a tiotropium salt

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7040314B2 (en) 2002-09-06 2006-05-09 Philip Morris Usa Inc. Aerosol generating devices and methods for generating aerosols suitable for forming propellant-free aerosols
US20070086957A1 (en) * 2005-10-10 2007-04-19 Thierry Bouyssou Combination of medicaments for the treatment of respiratory diseases
US20110135582A1 (en) * 2005-10-10 2011-06-09 Boehringer Ingelheim International Gmbh Combination of medicaments for the treatment of respiratory diseases

Also Published As

Publication number Publication date
IL122752A0 (en) 1998-08-16
CZ288337B6 (en) 2001-05-16
NO976084D0 (en) 1997-12-23
PL186196B1 (en) 2003-11-28
AU721566B2 (en) 2000-07-06
BG64112B1 (en) 2004-01-30
KR100392280B1 (en) 2003-11-19
RU2223750C2 (en) 2004-02-20
US8062626B2 (en) 2011-11-22
PL324243A1 (en) 1998-05-11
AR002614A1 (en) 1998-03-25
NO315452B1 (en) 2003-09-08
TW537903B (en) 2003-06-21
UA62917C2 (en) 2004-01-15
HU223072B1 (en) 2004-03-01
SK282468B6 (en) 2002-02-05
CA2225601A1 (en) 1997-01-16
DK0835098T3 (en) 2002-10-07
CZ419297A3 (en) 1998-06-17
HUP9901710A2 (en) 1999-10-28
TR199701711T1 (en) 1998-05-21
EP0835098B1 (en) 2002-09-04
BR9609307B1 (en) 2010-03-09
CN1189096A (en) 1998-07-29
KR19990028408A (en) 1999-04-15
JP3875993B2 (en) 2007-01-31
EP0835098A1 (en) 1998-04-15
PE11098A1 (en) 1998-03-17
JPH11508547A (en) 1999-07-27
DE19625027A1 (en) 1997-01-02
EG23912A (en) 2007-12-30
IL122752A (en) 2001-07-24
MY116535A (en) 2004-02-28
ZA965411B (en) 1996-12-27
NZ312662A (en) 2001-03-30
SA96170213B1 (en) 2006-03-06
WO1997001329A1 (en) 1997-01-16
SK176497A3 (en) 1998-06-03
EE03509B1 (en) 2001-10-15
EE03509B2 (en) 2015-02-16
US20060127322A1 (en) 2006-06-15
EE9700371A (en) 1998-06-15
PT835098E (en) 2002-12-31
DE59609627D1 (en) 2002-10-10
BG102172A (en) 1998-10-30
US20080102037A1 (en) 2008-05-01
AU6414496A (en) 1997-01-30
HUP9901710A3 (en) 2000-06-28
MX9800125A (en) 1998-03-31
SI0835098T1 (en) 2003-02-28
US20030165435A1 (en) 2003-09-04
ATE223203T1 (en) 2002-09-15
US6491897B1 (en) 2002-12-10
ES2183001T3 (en) 2003-03-16
CN1086575C (en) 2002-06-26
CA2225601C (en) 2003-10-14
BR9609307A (en) 1999-07-06
NO976084L (en) 1997-12-23

Similar Documents

Publication Publication Date Title
US8062626B2 (en) Stable pharmaceutical budesonide preparation for producing propellant-free aerosols
CN1097455C (en) New aqueous medicament preparations for the production of propellent gas-free aerosols
US7470422B2 (en) Method for the production of propellant gas-free aerosols from aqueous medicament preparations
AU3257000A (en) New, stable medicinal compositions for generating propellant-free aerosols
CZ296966B6 (en) Pharmaceutical composition
MXPA99005660A (en) New aqueous medicament preparations for the production of propellent gas-free aerosols

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载